K-232 phase 3 comparative study compared to brimonidine ophthalmic solution in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH)
Latest Information Update: 13 Apr 2023
Price :
$35 *
At a glance
- Drugs Brimonidine/ripasudil (Primary) ; Brimonidine
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kowa
- 01 Apr 2023 Results comparing efficacy and safety of ripasudil-brimonidine fixed-dose combination to ripasudil or brimonidine in two studies ( JapicCTI-205160 & JapicCTI-205159) published in the American Journal of Ophthalmology.
- 15 Dec 2021 Status changed from recruiting to completed.
- 22 Apr 2020 New trial record